Cansino Biologics Inc (SHG:688185) — Market Cap & Net Worth
Market Cap & Net Worth: Cansino Biologics Inc (688185)
Cansino Biologics Inc (SHG:688185) has a market capitalization of $1.03 Billion (CN¥7.04 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #9007 globally and #2413 in its home market, demonstrating a -6.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cansino Biologics Inc's stock price CN¥61.59 by its total outstanding shares 114372901 (114.37 Million). Analyse 688185 cash flow conversion to see how efficiently the company converts income to cash.
Cansino Biologics Inc Market Cap History: 2020 to 2026
Cansino Biologics Inc's market capitalization history from 2020 to 2026. Data shows change from $6.23 Billion to $1.03 Billion (-27.57% CAGR).
Cansino Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cansino Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.21x
Cansino Biologics Inc's market cap is 1.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $6.23 Billion | $24.89 Million | -$396.64 Million | 250.26x | N/A |
| 2021 | $4.99 Billion | $4.30 Billion | $1.91 Billion | 1.16x | 2.61x |
| 2022 | $2.44 Billion | $1.03 Billion | -$909.43 Million | 2.36x | N/A |
| 2023 | $1.25 Billion | $357.08 Million | -$1.48 Billion | 3.49x | N/A |
| 2024 | $1.02 Billion | $846.34 Million | -$378.88 Million | 1.21x | N/A |
Competitor Companies of 688185 by Market Capitalization
Companies near Cansino Biologics Inc in the global market cap rankings as of May 7, 2026.
Key companies related to Cansino Biologics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #501 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #530 globally with a market cap of $50.06 Billion USD ( CN¥342.11 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #541 globally with a market cap of $49.01 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #574 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #501 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.06 Billion | CN¥53.63 |
| #541 | Zoetis Inc | NYSE:ZTS | $49.01 Billion | $111.22 |
| #574 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $43.83 |
Cansino Biologics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Cansino Biologics Inc's market cap moved from $6.23 Billion to $ 1.03 Billion, with a yearly change of -27.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.03 Billion | -2.00% |
| 2025 | CN¥1.05 Billion | +2.95% |
| 2024 | CN¥1.02 Billion | -18.08% |
| 2023 | CN¥1.25 Billion | -48.97% |
| 2022 | CN¥2.44 Billion | -51.00% |
| 2021 | CN¥4.99 Billion | -19.93% |
| 2020 | CN¥6.23 Billion | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Cansino Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cansino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more